Core Viewpoint - The article discusses the initiation of a Phase III clinical trial for HDM1002 tablets, aimed at evaluating its efficacy and safety compared to Dapagliflozin in adult patients with type 2 diabetes who have inadequate blood sugar control after Metformin treatment [2][3]. Group 1: Clinical Trial Details - The clinical trial is registered under CTR20252647 and involves a multicenter, randomized, double-blind, positive drug parallel-controlled study [3]. - The primary objective of the trial is to verify that HDM1002 is not inferior to Dapagliflozin in terms of blood sugar control [2][3]. - HDM1002 is developed by Huadong Medicine and is a potent, selective GLP-1 receptor agonist with global intellectual property rights [3]. Group 2: Mechanism and Previous Research - Preclinical studies indicate that HDM1002 effectively activates GLP-1R, promotes cAMP production, significantly improves glucose tolerance, lowers blood sugar, and aids in weight loss while demonstrating good safety [3]. - In March of this year, another Phase III clinical trial (registration number CTR20251246) was initiated to assess HDM1002's potential in weight management among overweight or obese populations [3]. Group 3: Future Expectations - The weight management study is based on controlled dietary caloric intake and increased physical activity, with the first subject already enrolled and the primary endpoint expected to be completed by June 30 of the following year [3].